Experience with mesocaval shunt with autologous jugular vein interposition in patients with Budd-Chiari syndrome

Simple item page
dc.contributor.authorIlkgul Ö.
dc.contributor.authorKilic M.
dc.contributor.authorIçöz G.
dc.contributor.authorZeytunlu M.
dc.contributor.authorDemirpolat G.
dc.contributor.authorAkyildiz M.
dc.contributor.authorTokat Y.
dc.contributor.authorParildar M.
dc.contributor.authorMemis A.
dc.date.accessioned2024-07-22T08:23:57Z
dc.date.available2024-07-22T08:23:57Z
dc.date.issued2005
dc.description.abstractBackground/Aims: In the present era of interventional radiology and liver transplantation, the role of mesocaval shunt surgery for portal hypertension in Budd-Chiari syndrome is reviewed. Methodology: This study analyzed the management of 35 patients with Budd-Chiari syndrome between June 1994 and June 2004 in our institution. During this 10-year interval, 31 of the 35 patients with Budd-Chiari syndrome underwent shunt procedures and four patients underwent liver transplantation. Mesocaval shunts were preferred in 27 patients and seven of these patients required prior caval stenting. One portocaval shunt was performed in a patient having a thrombosed mesocaval shunt. In all mesocaval shunt procedures the patient's internal jugular vein was used as an interposition graft between the superior mesenteric vein and inferior vena cava. In four patients with thrombosed vena cava a mesoatrial shunt was performed using polytetrafluoroethylene graft while four patients with established cirrhosis underwent orthotopic liver transplantation. Results: In the group of mesocaval shunts, 3 patients were lost in the early postoperative period with a mortality rate of 11%, 2 of them due to thrombosed shunts and one of them due to pneumonia. The median follow-up was 42 months (6-120 months) and one patient experienced shunt thrombosis and died afterwards due to the complications of portal hypertension. In the whole series the patency rate of the mesocaval shunt was 89%. Conclusions: Patients with Budd-Chiari syndrome can be managed by a combination of shunt surgery, interventional radiology and liver transplantation. Our results demonstrate the effectiveness of mesocaval shunt procedure with autologous jugular vein interposition to maintain long-term patency and survival. © H.G.E. Update Medical Publishing S.A.
dc.identifier.issn01726390
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19767
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAnastomosis, Surgical
dc.subjectFemale
dc.subjectGraft Occlusion, Vascular
dc.subjectHepatic Vein Thrombosis
dc.subjectHumans
dc.subjectHypertension, Portal
dc.subjectJugular Veins
dc.subjectLiver Function Tests
dc.subjectLiver Transplantation
dc.subjectMagnetic Resonance Angiography
dc.subjectMale
dc.subjectMesenteric Veins
dc.subjectMiddle Aged
dc.subjectPostoperative Complications
dc.subjectRadiology, Interventional
dc.subjectStents
dc.subjectUltrasonography, Doppler, Duplex
dc.subjectVena Cava, Inferior
dc.subjectadult
dc.subjectautograft
dc.subjectBudd Chiari syndrome
dc.subjectclinical article
dc.subjectfemale
dc.subjectfollow up
dc.subjectgraft patency
dc.subjecthuman
dc.subjectinferior cava vein
dc.subjectinterventional radiology
dc.subjectjugular vein
dc.subjectliver cirrhosis
dc.subjectliver transplantation
dc.subjectmale
dc.subjectmesenteriocaval anastomosis
dc.subjectmesoatrial shunt
dc.subjectpneumonia
dc.subjectpolitef implant
dc.subjectportal hypertension
dc.subjectportocaval shunt
dc.subjectpriority journal
dc.subjectreview
dc.subjectshunt thrombosis
dc.subjectshunting
dc.subjectstent
dc.subjectsuperior mesenteric vein
dc.subjectsurgical mortality
dc.subjectsurgical technique
dc.subjectvein graft
dc.subjectvein thrombosis
dc.titleExperience with mesocaval shunt with autologous jugular vein interposition in patients with Budd-Chiari syndrome
dc.typeReview

Files

Collections

Scopus Koleksiyonu